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Abstract
A simple theoretical model for the cellular pharmacody-
namics of cisplatin is presented. The model, which
takes into account the kinetics of cisplatin uptake by
cells and the intracellular binding of the drug, can be
used to predict the dependence of survival (relative to
controls) on the time course of extracellular exposure.
Cellular pharmacokinetic parameters are derived from
uptake data for human ovarian and head and neck
cancer cell lines. Survival relative to controls is
assumed to depend on the peak concentration of
DNA-bound intracellular platinum. Model predictions
agree well with published data on cisplatin cytotoxicity
for three different cancer cell lines, over a wide range of
exposure times. In comparison with previously pub-
lished mathematical models for anticancer drug phar-
macodynamics, the present model provides a better fit
to experimental data sets including long exposure times
(100 hours). The model provides a possible explan-
ation for the fact that cell kill correlates well with area
under the extracellular concentration–time curve in
some data sets, but not in others. The model may be
useful for optimizing delivery schedules and for the
dosing of cisplatin for cancer therapy.
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Introduction
The drug cisplatin, used in anticancer therapy for decades
[1], has significant adverse side effects. The optimization of
the dosing and delivery schedule can potentially minimize
adverse effects while maintaining efficacy [2]. A consensus
on the optimal schedule of the administration of cisplatin does
not appear to have been reached. Kurihara et al. [3 ] stated
that ‘‘Standard therapy with DDP [cisplatin ] has been a single
bolus injection because the antitumor activity of this drug has
been considered to be dependent on its peak plasma
concentration.’’ However, Drewinko and Gottlieb [4 ] con-
cluded that a greater degree of killing was elicited with
treatment extended over a period of 30 hours. Several clinical
studies have compared continuous- infusion cisplatin with
bolus administration. Hayashi et al. [5 ] found no improve-
ment in response and no decrease in the toxicity for the
cancer of the esophagus treated with a 5-day continuous
infusion, whereas Salem et al. [6 ] reported the toxicity of this
schedule to be ‘‘mild’’ but were unable to assess the
antitumor efficacy. Dose- limiting toxicities have been asso-
ciated both with peak plasma levels [7 ] and with plasma area
under the concentration–time curve (AUC) [8]. Theoretical
pharmacodynamic models that predict tumor cell survival for
a given time course of drug exposure provide a rational basis
for the optimization of administration schedules, which
involves maximizing tumor cell kill under the constraint that
host toxicity must remain tolerable.
For cell cycle nonspecific drugs such as cisplatin, it has
been proposed that the AUC determines cytotoxicity,
independent of exposure time [9]. Table 1 lists experimental
studies that have provided data permitting assessment of the
dependence of cisplatin cytotoxicity on exposure time for a
given AUC. In some of these studies, when survival relative to
controls is graphed as a function of AUC, curves for different
exposure times clearly differ (e.g., Troger et al. [2 ] ), implying
that AUC alone is not predictive of survival. Similarly, AUC at
50% survival ( relative to controls) can vary with exposure
time [10]. In other studies, however, graphs of survival
versus AUC nearly coincide for all exposure times [11,12],
implying that AUC is predictive of cytotoxicity over the range
considered. In two cases [3,13], the authors concluded
that AUC predicted cytotoxicity, but their data imply a
dependence on exposure time. All of the studies that showed
AUC alone as being predictive were for exposure times of
24 hours or less. Taken together, these data indicate that
the assumption that cell kill depends on AUC, independent
of exposure time, does not adequately represent the
pharmacodynamics of cisplatin.
A number of other theoretical models have been proposed
to predict the dependence of cytotoxicity on the time course
of exposure. For cells exposed to a constant extracellular
concentration, the AUC is equal to CT, where C is the
concentration and T is the exposure time. An alternative,
more general, predictor of cell kill is CnT [14,15], where n
may depend on the drug and the tumor type. Curves for
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survival S relative to controls, when plotted versus either
extracellular AUC or CnT, typically have a sigmoidal shape
that can be approximated by a Hill - type equation:
S ¼ 1
1þ Axm ð1Þ
where A and m are constants. In the following, Eq. (1) with
x=AUC will be referred to as the ‘‘extracellular AUC model’’,
and with x=CnT as the ‘‘extracellular CnT model’’. For
concentration varying with time, CnT can be replaced by the
time integral of C( t )n. Levasseur et al. [11] proposed a
model with several additional parameters, combining the
dependence of cell kill on CnT with a Hill - type equation.
They fitted the model to experimental results for several
drugs, including cisplatin. Because an exponent in their
model has a quadratic dependence on T, their model is not
applicable for exposures longer than 24 hours— the
maximum in their data set. Their model has no clear
generalization to the case of time-varying concentration.
Gardner [16] developed an ‘‘exponential kill’’ model based
on a consideration of the kinetics of cell kill. This model
contains some assumptions that restrict its applicability. It
implies that the AUC required for a given level of cell kill
decreases with exposure time to cell cycle–nonspecific
drugs, whereas many drugs ( including cisplatin ) show the
opposite effect [17]. These four models are summarized in
Table 2. The survival relative to controls S is defined as the
number of surviving cells after a single cycle of exposure,
divided by the number of surviving cells at the same time
point in untreated controls. This measure, which does not
describe the kinetics of cell kill during the treatment period, is
the most relevant for optimizing therapy.
Cisplatin acts by binding to cellular DNA, and must enter
cells to be lethal. The dependence of cell kill on the time
course of extracellular exposure must therefore reflect the
kinetics of cellular drug uptake and binding to intracellular
targets. As yet, no theoretical model for the pharmacody-
namics of chemotherapy drugs that meets the following
requirements has been developed: ( i ) it is based on a
consideration of the kinetics of drug entry into cells and
binding within cells; ( ii ) it can be used to predict the response
to an arbitrary time course of extracellular exposure (as
occurs in actual cancer therapy); and ( iii ) it is applicable to all
data sets with long exposure times (>100 hours). The goal of
the present work is to develop such a model, and to compare
its predictions with those of the previously proposed models
listed in Table 2.
Cisplatin reacts both inside and outside the cell to produce
a number of platinum species, and transport across the
cellular and nuclear membranes has different kinetics for
each species. Presently available data do not permit the
determination of the individual kinetics of each of these
reaction and transport processes. However, in kinetic
systems, it is often possible to lump several species together
Table 1. Summary of Literature Studies on the Predictive Value of Extracellular AUC for the Survival of Human Cancer Cell Lines After Exposure to Cisplatin.
Source Cell / tumor type AUC predicted
cell survival?
Range of exposure
times (hours )
Replot
needed*
Troger et al. [ 2 ] Head and neck cancer No 1–121 No
Nozue et al. [ 10 ] Human gastric cancer No 1–72 Yes
Matsushima et al. [ 33 ] Human lung carcinoma PC-7 No 1–24 Yes
Levasseur et al. [ 11 ] Human ovarian and colon carcinomas Yes 1–24 Yes
Rupniak et al. [ 34 ] Human ovarian carcinoma Maybe 1–18 Yes
Ma et al. [ 12 ] IGROV1 ovarian Yes 1–20 Yes
Kurihara et al. [ 3 ] Human gastric carcinoma No 1–25 Yes
Los et al. [ 35 ] CC531 ( colon carcinoma ) No 1–4 Yes
Erlichman et al. [ 13 ] MGH-U1 human bladder cancer No 1.3–4.4 No
*Data are plotted versus extracellular concentration in the cited study.
Table 2. Previous and Proposed Models for Cisplatin Cellular Pharmacodynamics.
Name of model Reference Equations Number of free
parameters
Extracellular AUC model Ozawa et al. [ 9 ] S=1 / ( 1+A(AUC )m )
where
AUC=
R
0
Tce(t )dt
2
Extracellular CnT model Skipper [ 14 ] and
Adams et al. [ 15 ]
S=1 / ( 1+A(AUCn )m )
where
AUCn=
R
0
Tce( t )
ndt
3
Levasseur et al. model Levasseur et al. [ 11 ] S=B+ (SconB ) ce
g
cge þ ICg50
IC50= (k /T )
1 / n
g=g0+g1T+g2T
2
7
Gardner model Gardner [ 16 ] S=Exp[ 1b(1e ace )T ] 2
Peak intracellular model Present study S=1 / ( 1+A(c i
peak
)m ) and Eq. (2 ) 2 or 4*
Peak -bound
intracellular model
Present study S=1 / ( 1+A(c k
peak
)m ) and Eqs. ( 2 ) and (3 ) 3 or 5*
*The two parameters relating to cellular uptake may be obtained separately ( see text ).
 
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and obtain a useful model, and this approach is taken here.
The resulting model is relatively simple but yields predictions
of cytotoxicity that are consistent with observations over a
range of different exposure conditions.
Materials and Methods
The elements of the model for drug uptake and DNA
binding are shown schematically in Figure 1. The quantities
ce, c i, c k, and c i
0 refer to concentrations of platinum
species pools: ce, extracellular concentration; c i, intra-
cellular concentration; c k, concentration bound to DNA; c i
0,
concentration released from DNA as a result of DNA
repair. Platinum species released during DNA repair are no
longer available for binding [18]. The intracellular concen-
tration c i includes platinum that is aquated, hydrolyzed
inside the nucleus, bound to RNA, bound to other non-
DNA proteins, and so on, but excludes the concentrations
ck and c i
0. Experimental data [19,20] imply that DNA-
bound intracellular platinum is a small fraction of total
intracellular platinum. Therefore, both ck and c i
0 are
assumed to be much smaller than c i.
A reversible exchange of drug between extracellular and
intracellular compartments is assumed, and cellular uptake
is therefore described by:
dc i
dt
¼ k1cek 01c i; ð2Þ
where t is time, and k1 and k1
0 are constants. The uptake rate
is assumed to be linear in ce based on numerous studies
showing such a linear relation at any time [2,21–25]. The
removal of platinum from the intracellular pool by DNA
binding is neglected in this equation because ck and c i
0 are
much smaller than c i. Eq. (2) was solved analytically to give
an expression for c i as a function of time.
The values for the constants k1 and k1
0 were determined
by minimizing the mean square deviation of predicted
intracellular concentration c i (neglecting the part bound to
DNA) from measured values for cellular uptake of cisplatin
by the ovarian cancer cell line 2008 [26], using the
software package Mathematica (Wolfram Research, Cham-
paign, IL). In these data, extracellular concentration is 1.0
mol/ l cisplatin=0.195 g/ml Pt, based on one Pt atom
(atomic weight=195) per cisplatin molecule. Intracellular
concentrations, given in picomoles of Pt per milligram of
protein, are converted to micrograms of Pt per milliliter,
based on 1 mg of protein=3 l of cell volume [26]. The same
model, with the same values of k1 and k1
0, was used to fit the
data of Troger et al. [2 ] for a head and neck cancer cell line
with the cell volume, which is used to convert intracellular
concentrations from units of nanograms of Pt per 106 cells,
treated as a free parameter.
This cellular pharmacokinetic model was used as a basis
for developing a cellular pharmacodynamic model. Because
cisplatin kills cells by binding to DNA in the cell nucleus, it is
reasonable to assume that cell kill correlates more directly
with measures of intracellular exposure than with measures
of extracellular exposure. Survival relative to controls S, as
defined previously, is then given by Eq. (1), with x replaced
by a measure of intracellular exposure. Intracellular AUC is
one such measure. As already mentioned, cellular uptake is
assumed to be linear in the extracellular concentration ce,
based on several experimental studies, which implies that
intracellular AUC is linearly related to extracellular AUC.
Figure 1. Schematic representation of proposed model. Concentrations of
platinum are: ce, extracellular; ci, intracellular non -DNA bound; ck, intracellular
DNA -bound; ci
0, released from DNA as a result of DNA repair. Arrows indicate
transport or reaction processes. The concentration ci is much larger than ck
and ci
0.
Figure 2. Fits of cellular pharmacokinetic model to data on the uptake of
platinum by human cancer cells in vitro. Curves show model predictions. (A )
Data of Andrews et al. [ 26 ] for ovarian carcinoma cells. Extracellular
concentration: 0.195 g /ml Pt. (B ) Data of Troger et al. [ 2 ] for head and
neck cancer cells. Extracellular concentrations: (l ) 0.65 g /ml Pt; (& ) 1.62
g /ml Pt; (~ ) 3.2 g /ml Pt; and (! ) 6.5 g /ml Pt.
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Using intracellular AUC as a measure is therefore mathe-
matically equivalent to the extracellular AUC model as
already described, for which results are presented below.
The alternative possibility that cell kill is related to peak
intracellular levels was therefore explored. Choosing x as
the peak intracellular concentration of platinum ( i.e., the
maximum value of c i achieved over time) gives the ‘‘peak
intracellular model’’ (Table 2).
Cisplatin kills cells by binding to cellular DNA and forming
adducts, whose formation may take some hours [27].
This suggests a pharmacodynamic model that correlates
cytotoxicity with the peak level of c k, the DNA-bound
platinum, rather than c i. According to the model (Figure 1),
the DNA-bound platinum concentration is governed by:
dck
dt
¼ k2c ik3ck ð3Þ
where k2 is a rate constant for binding to DNA, and k3 is a
rate constant for DNA repair. Eq. (3) was solved analytically
to give an expression for c i as a function of time. The survival
relative to controls S is then given by Eq. (1), where x is
the peak value of c k achieved over time, denoted ck
peak
( ‘‘peak-bound intracellular model’’; Table 2).
This model contains six unknown parameters, k1, k1
0, k2,
k3, A, andm. The values of ck predicted by the model at each
instant are proportional to k2. In the absence of measured
values of c k, values of k2 and A cannot be deduced from
survival data because S depends on them mathematically
only through a combined parameter Ak2
m. Therefore, A was
set to an arbitrary fixed value [1 (g/ml)m ] in this model,
giving five unknown parameters. Values of c k and c i
0
predicted by the model are relative and cannot be compared
in absolute terms with c i.
Table 2 summarizes the six models to be compared
( i.e., the four previous models discussed above and the
two proposed here). For each model, best fits were
determined between predicted values of the survival S
relative to controls and the measured values for human
head and neck cancer cells [2 ], the human ovarian
cancer cell line A2780 [11], and human gastric cancer
cells [3 ]. The parameters were varied to minimize the root
mean square deviation between calculated and experi-
mental values of S, using Mathematica or a Fortran
implementation of the method of steepest descent. Data
for tumor cell survival and extracellular concentration were
read from the published graphs. In one study [11], not all
data points could be read because points for different
exposure times overlapped. For the peak intracellular and
peak-bound intracellular models, the values of k1 and k1
0
determined from the cell uptake model were used to fit
the Troger et al. [2 ] cell kill data. Cell uptake data are not
available for the cell lines in the other studies [3,11], so
k1 and k1
0 were fit to the cytotoxicity data along with the
other parameters.
Results
Figure 2 shows the fit of the cellular uptake model to the
uptake data. A close fit to the data of Andrews et al. [26]
was obtained with k1=2.635 hour
1 and k1
0=0.1184 hour1.
With these same values for k1 and k1
0, the optimal value of
cell volume to fit the Troger et al. [2 ] drug uptake data was
computed as 2.17109 ml. This fits their drug uptake data
well, and is a physiologically reasonable value.
The best - fit parameter values for the six models, applied
to the three cytotoxicity data sets, are summarized in Table 3.
Table 3. Best -Fit Model Parameters for Cisplatin Cytotoxicity Data Sets.
Model Parameters for
Troger et al. [ 2 ] data
Parameters for
Levasseur et al. [ 11 ] data
Parameters for
Kurihara et al. [ 3 ] data
Extracellular AUC model A=0.2033, m=1.229 A=0.4047, m=1.882 A=0.1786, m=0.5574
Extracellular CnT model n=1.303, A=0.2988, m=0.9991 n=0.8762, A=0.2603, m=2.171 n=3.313, A=0.3920, m=0.1539
Levasseur et al. [ 11 ] model k=3.670,
n=1.306,
B=0*,
Econ=0.9811,
g0= 1.621,
g1=0.05718 hour
 1,
g2= 0.0004485 hour 2
k=1.855,
n=0.8683,
B=0.006507,
Econ=0.9974,
g0= 1.856,
g1=  0.05292 hour 1,
g2=0.002680 hour
 2
k=2.832,
n=1.652,
B=0*,
Econ=1.514,
g0= 0.4066,
g1= 0.006071 hour 1,
g0=0.0002250 hour
 2
Gardner [ 16 ] model a=0.0006284, b=271.0 a=0.1156, b=3.691 a=0.01265, b=2.077
Peak intracellular model (k1=2.635 hour
 1 ),
(k1
0=0.1184 hour 1 ),
A=0.1477,
m=1.212
k1=0.04629 hour
 1,
k1
0=0.0002569 hour 1,
A=131.4,
m=1.881
(k1=2.635 hour
 1),
(k1
0=0.1184 hour 1),
A=0.1573,
m=0.5465
Peak -bound
intracellular model
(k1=2.635 hour
 1 ),
(k1
0=0.1184 hour 1 ),
k2=0.2024 hour
 1,
k3=0.4707 hour
 1,
m=1.381
k1=0.3267 hour
 1,
k1
0=0.02413 hour 1,
k2=3.745 hour
 1,
k3=1.441 hour
 1,
m=1.956
(k1=2.635 hour
 1 ),
(k1
0=0.1184 hour 1),
k2 /k3=0.02837,
(k3= infinity ),
m=0.5715
Where units are not shown, concentrations are in micrograms per milliliter and time is in hours. Values in parentheses were determined from independent uptake
data [ 2 ], or were chosen arbitrarily because they do not significantly affect the fit [ 3 ].
*B represents the plateau value of survival ( fraction of controls ) in the high - concentration limit, and therefore cannot be less than 0. This constraint was included in
the optimization process.
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Figures 3–5 show the resulting fit of the models to the
cytotoxicity data sets of Troger et al. [2 ], Levasseur et al.
[11], and Kurihara et al. [3 ], respectively. The data of
Kurihara et al. [3 ] are plotted in Figure 5 as a function of
extracellular AUC to show the trend for survival ( increasing
with exposure time for a given AUC), contrary to the stated
conclusion [3] that AUC predicts cell kill. For each plot in
Figures 3–5, the residual ( root mean square) deviation
between measured and predicted values is shown within the
plot area. For each data set considered, the peak-bound
intracellular model yields the best fit, as indicated by the
lowest residual.
Discussion
The uptake model used here has some similarities to that of
Sadowitz et al. [18], which modeled cisplatin cell uptake,
intracellular reaction with thiols, and binding to DNA, and
distinguished between intracellular nuclear and extranuclear
cisplatin. With some simplifications, their model contained
four unknown parameters that were obtained by fitting data
on DNA adducts as a function of extracellular cisplatin for a
2-hour exposure. However, the present uptake model
(Eq. 2), with only two fitted parameters, provides an
adequate fit to the uptake data. Distinguishing between
more intracellular species would result in more unknown
parameters, which could not be estimated reliably from the
currently available data.
Previous experimental studies (Table 1) have led to
conflicting conclusions regarding the validity of extracellular
AUC as a predictor of cytotoxicity. The present results
provide a possible explanation. When applied to the data
sets of Levasseur et al. [11] and Kurihara et al. [3 ], the
extracellular AUC model yields fairly good fits (Figures 4
and 5), but the Troger et al. [2 ] data show large systematic
deviations from the model predictions (Figure 3). The latter
data cover a wider range of exposure times, and the
deviations are greatest for the longest exposure time
(121 hours), which gives only slightly more cell kill than an
11-hour exposure at the same concentration. For exposures
in this range, a decrease in concentration is not fully
compensated for by a corresponding increase in exposure
time. By definition, the extracellular AUC model cannot show
such behavior. The extracellular CnT model incorporates
such behavior, but is still unable to provide a good fit to the
data for very long exposures.
The model of Levasseur et al. [11] provides a good fit to
the experimental data set obtained by the same authors
Figure 3. Best fits of six cytotoxicity models to the data of Troger et al. [ 2 ] for human head and neck cancer cells. Exposure times: (l ) 1 hour; (& ) 2 hours;
(~ ) 11 hours; and (! ) 121 hours. Curves: model predictions. Res: root mean square residual deviation between experimental data and model.
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(Figure 4). However, this model is less successful at fitting
the Troger et al. [2 ] data set (Figure 3) because it does not
show the correct behavior at low concentrations and long
exposure times. When applied to the Kurihara et al. [3 ] data
(Figure 5), this model gives a good fit, but the parameter
values then give survival relative to controls substantially
greater than 1 at very low concentrations (which would imply
that the drug was actually promoting tumor growth).
Similarly, the model of Gardner [16] yields a good fit to the
data set of Levasseur et al. [11 ] but fails to fit the data set of
Troger et al. [2 ] for long exposure times. When applied to
the data set of Kurihara et al. [3 ], it exhibits the ‘‘plateau’’
feature of this model (asymptote to nonzero survival at high
concentration). The dependence of this plateau is dictated
by the behavior of the curves in the steep descent phase.
The inability to adjust these two behaviors independently
limits the model’s ability to fit cytotoxicity data over a wide
range of concentrations.
In the models proposed in the present study, cell kill
depends on peak intracellular cisplatin levels. When the
extracellular concentration is reduced below a threshold
level, the peak intracellular level is correspondingly limited,
no matter how long the exposure time (Figure 6). For very
long exposure times, the survival relative to controls there-
fore approaches a limit that depends only on the concen-
tration. This feature of the peak-bound intracellular model
accounts for its ability to provide a good fit to the Troger et al.
[2 ] data, including those for 121-hour exposure (Figure 3).
Under some conditions, the proposed models can yield
results similar to the extracellular AUC model, as shown in
Figure 4. This may be understood by the following argument.
For exposure times that are short enough that the free
intracellular concentration remains much less than the
extracellular level, the cellular uptake model of Eqs. (2)
and (3) can be integrated to give:
cpeaki ¼ k1
Z T
0
cedt ð4Þ
Peak intracellular level is then proportional to extracellular
AUC, and a close correlation between cell kill and AUC is
expected according to the proposed models. The time at
which intracellular free concentration approaches the extrac-
ellular concentration is on the order of 1/k1
0, and Table 3
shows that this kinetic parameter has different values for
different cell lines: 8 hours for the Troger et al. [2 ] data, 41
hours for the Levasseur et al. [11] data, and 7 hours for the
Kurihara et al. [3 ] data. In the case of Levasseur et al. [11],
the exposure times, ranging from 1 to 24 hours, are all less
Figure 4. Best fits of six cytotoxicity models to the data of Levasseur et al. [ 11 ] for a human ovarian cancer cell line. Exposure times: (l ) 1 hour; (& ) 2 hours;
(~ ) 3 hours; (! ) 4 hours; (6) 6 hours; (5 ) 9 hours; (4 ) 12 hours; and (5 ) 24 hours. Curves: model predictions. Res: root mean square residual deviation
between experimental data and model.
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than the intracellular equilibration time. Therefore, the peak
intracellular model yields almost identical results to those of
the extracellular AUC model (Figure 4).
Of the six models examined, the peak-bound intra-
cellular model consistently yields the best fit to the data
considered. The key feature of this model is that cell kill is
correlated with the peak intracellular level of DNA-bound
platinum. The connection between cytotoxicity and peak
intracellular bound concentrations is also supported by
results for high-dose cisplatin therapy (Figure 14-4 of
Reed et al. [1 ] ) showing that peak platinum–DNA adduct
levels correlate with response to treatment. A correlation of
cell kill with peak intracellular levels has also been found
for doxorubicin [28]: Data on cell kill for various exposure
times collapsed onto a single curve when plotted against
the intracellular concentration at the time extracellular
exposure ended ( i.e., the peak intracellular concentration).
The Troger et al. [2 ] data set provides the most stringent
test of the six models, and the validity of this data set is
therefore critical for the present study. Ma et al. [12]
concluded from their experiments that AUC, corrected for
protein binding, predicted cell kill well, and conjectured that
the finding of Troger et al. [2 ]— that cell kill as a function of
AUC was substantially different at 121 hours than at shorter
times— was an artifact of their not correcting for protein
binding in the medium. This reasoning is questionable for
several reasons. Firstly, the experiments of Ma et al. [12]
covered the range 1 to 20 hours, with no data for exposure
Figure 5. Best fits of six cytotoxicity models to the data of Kurihara et al. [ 3 ] for a human gastric cancer cell line. Exposure times: (l ) 1 hour; (& ) 5 hours;
(~ ) 10 hours; and (! ) 25 hours. Curves: model predictions. Res: root mean square residual deviation between experimental data and model.
Figure 6. Survival relative to controls as predicted by the peak -bound
intracellular model for a wide range of exposure times, showing a threshold
concentration below which no substantial cell kill can be achieved, regardless
of exposure time. Parameter values are those for the Levasseur et al. [ 11 ]
data set.
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times as long as those of Troger et al. [2 ]. Secondly, Ma et al.
[12] used a medium containing albumin to simulate protein
binding in plasma. However, albumin may not be the major
ligand of platinum in rat serum [29]. Thirdly, Gamelin et al.
[30] found that the ratio of ultrafilterable to total platinum in
plasma was nearly constant at 6% over time, suggesting that
similar correlations should be found whether cell survival is
plotted versus total or ultrafilterable platinum. Thus, the
findings of Troger et al. [2 ] of significant time dependence
cell survival relative to controls for a given AUC are unlikely
to be artifactual as suggested by Ma et al. [12].
It might be thought that the decreased cell kill at the same
extracellular AUC, observed by Troger et al. [2 ] and others at
longer exposure times, could be explained simply in terms of
the development of a resistant population when cells are
exposed to drug for longer times. This possibility was
examined under the following assumptions: ( i ) the cell kill
for the sensitive population depends only on AUC; and ( ii )
both the resistant and sensitive populations grow exponen-
tially at the same rates when untreated, as expected for the
conditions of in vitro studies [2]. A simple mathematical
analysis shows that, under these assumptions, the increase
in survival relative to controls due to the presence of resistant
cells is independent of the exposure time.
In summary, of the six models considered, the peak-
bound intracellular model yields the best fit to three separate
sets of data on for cisplatin toxicity involving different types of
cultured tumor cells, including a set with long (121 hours)
exposure time. Important features of this model are: ( i ) it is
based on the assumption that cell kill depends on the peak
level of DNA-bound intracellular platinum; ( ii ) for relatively
short exposure times, it yields predictions similar to those
resulting from AUC-type models; ( iii ) for a given AUC,
reduced responses are predicted at very long exposure
times; ( iv ) it predicts that a threshold concentration is
needed for any antitumor effect; (v) it involves a small
number of fitted parameters, only three if separate cell
uptake data are available; and (vi ) it is applicable to the case
of variable extracellular concentration as a function of time.
Currently, cisplatin is administered intravenously in the
clinic either by bolus injection or continuous infusion. Even
with bolus injection, much of the AUC comes from a long
‘‘tail’’ of exposure at low concentrations. The present model
suggests that this tail of exposure after peak-bound intra-
cellular levels have been achieved provides no therapeutic
benefit, although it presumably contributes to toxicity
(because mucositis and hematologic toxicity appear to
correlate with plasma AUC). The tail could be eliminated
by using sodium thiosulfate to deactivate cisplatin system-
atically. Muldoon et al. [31] gave sodium thiosulfate to
guinea pigs 2 hours after cisplatin treatment, and found
reduced ototoxicity, suggesting that this toxicity may also be
related to the tail of exposure rather than the peak.
The model developed here was based on data for in vitro
response of cells to drug. How closely in vivo cellular
response correlates with in vitro response is therefore an
important question. For some drugs, the in vivo environment,
in which each cell is surrounded three-dimensionally by
other cells and where cells may not be actively cycling due to
limited resources or other reasons, has been found to result
in less drug sensitivity. The study of Erlichman et al. [32]
found no difference in response to cisplatin between cells
grown as spheroids including necrotic cores, cells extracted
from xenografts, and cells grown in monolayers. This
suggests that for the drug cisplatin, in vivo response can
be predicted by in vitro response at the same exposure.
A pharmacodynamic model such as the one proposed
here is an essential component of a rational strategy for
determining the optimal dose and schedule of cisplatin
administration. However, further information about the
relationship between plasma exposure and host toxicity,
and between plasma exposure and tumor extracellular
exposure, is also needed as part of such a strategy. Models
similar to the one presented here may also be useful for other
drugs that act intracellularly, not only for optimizing the
administration of drugs in the clinical setting but also as a
framework for analyzing in vitro cytotoxicity data when
screening for new drugs.
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